Advertisement
Advertisement
At close: 04:00PM EST
After hours:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 221.46 |
| Open | 220.01 |
| Bid | 218.39 x 1400 |
| Ask | 224.82 x 1100 |
| Day's Range | 218.10 - 224.80 |
| 52 Week Range | 189.40 - 262.38 |
| Volume | |
| Avg. Volume | 576,916 |
| Market Cap | 32.974B |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | 40.88 |
| EPS (TTM) | 5.49 |
| Earnings Date | Apr 26, 2023 - May 01, 2023 |
| Forward Dividend & Yield | 1.76 (0.77%) |
| Ex-Dividend Date | Feb 08, 2023 |
| 1y Target Est | 257.57 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
6% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for RMD
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- ResMed Inc.RMD: Lowering target price to $237.00RESMED INC has an Investment Rating of HOLD; a target price of $237.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.RatingFair ValueEconomic Moat6 days agoArgus Research
- Insider Monkey
ResMed Inc. (NYSE:RMD) Q2 2023 Earnings Call Transcript
ResMed Inc. (NYSE:RMD) Q2 2023 Earnings Call Transcript January 26, 2023 ResMed Inc. beats earnings expectations. Reported EPS is $1.66, expectations were $1.62. Operator: Hello and welcome to the ResMed Second Quarter Fiscal Year 2023 Earnings Call. At this time, all participants are in a listen-only mode. As a reminder, this conference is being recorded. […]
- Simply Wall St.
ResMed Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS In Line
ResMed ( NYSE:RMD ) Second Quarter 2023 Results Key Financial Results Revenue: US$1.03b (up 16% from 2Q 2022). Net...
- Zacks
ESLOY vs. RMD: Which Stock Is the Better Value Option?
ESLOY vs. RMD: Which Stock Is the Better Value Option?
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
